As Athira Pharma Inc. (ATHA) grapples with its current market position, real-time data from InvestingPro provides a clearer picture of the company's financial health. With a market capitalization of just $16.07 million, Athira Pharma's valuation reflects its struggles. The company's price-to-earnings (P/E) ratio stands at -0.14, indicating that investors are not expecting earnings to cover the stock price in the near term. This is further reinforced by a negative return on assets of -71.06% for the last twelve months as of Q2 2024, highlighting the company's difficulties in generating profit from its assets.